aspirin

Drug eluting balloon vs. second generation DES for restenotic lesions in bifurcations

Original Title: Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. Reference: Toru Naganuma et al. EuroIntervention 2016;11:989-995 Courtesy of del Dr. Santiago F. Coroleu.  PCI involving in-stent restenosis (ISR), especially in coronary bifurcations, is associated with high rates of recurrent restenosis and the need for new revascularization. Although drug<a href="https://solaci.org/en/2016/02/10/drug-eluting-balloon-vs-second-generation-des-for-restenotic-lesions-in-bifurcations/" title="Read more" >...</a>

Long Term Outcomes of Routine vs. Provisional T-stenting for De Novo Coronary Bifurcations: Five Year Outcomes of the BBK-I Trial

Original Title: “Long-term outcomes of routine versus provisional T-stenting for de novo coronary bifurcation lesions: five-year results of the Bifurcations Bad Krozingen I study”. Authors: Miroslaw Ferenc, MD; Mohamed Ayoub, MD; Hans-Joachim Büttner, MD; Michael Gick, MD; Thomas Comberg, MD; Jürgen Rothe, MD; Christian M. Valina, MD; Willibald Hochholzer, MD; Franz-Josef Neumann, MD. Division of Cardiology and<a href="https://solaci.org/en/2015/12/28/long-term-outcomes-of-routine-vs-provisional-t-stenting-for-de-novo-coronary-bifurcations-five-year-outcomes-of-the-bbk-i-trial/" title="Read more" >...</a>

Dual Antiplatelet Therapy after Everolimus Eluting Stenting

Original Title: Benefits and Risks of Extended Dual Antiplatelet Therapy after Everolimus-Eluting Stents. For the Dual Antiplatelet Therapy (DAPT) Study Investigators. Reference: James B. Hermiller et al. JACC: Cardiovascular Interventions 2015, online before print. The DAPT study had shown that continued aspirin plus thienopyridine beyond a year reduces ischemic events. Given the fairly low rate of thrombosis<a href="https://solaci.org/en/2015/12/11/dual-antiplatelet-therapy-after-everolimus-eluting-stenting/" title="Read more" >...</a>

DAPT Substudy: Score to Personalize Optimal Dual Antiaggregation Therapy Duration

Original Title: Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the DAPT Study. Presenter: Yeh RW. Optimal dual antiplatelet therapy duration for patients receiving stents has started to become clearer, but a new scoring method (DAPT Score) may help single out patients who could either benefit or suffer from extended<a href="https://solaci.org/en/2015/11/20/dapt-substudy-score-to-personalize-optimal-dual-antiaggregation-therapy-duration/" title="Read more" >...</a>

PEGASUS-TIMI 54 Subanalysis: Discontinuation of Ticagrelor Mostly Due to Dyspnea or Bleeding

Original Title: Long-term tolerability of ticagrelor for secondary prevention: insights from PEGASUS-TIMI 54 trial. Presenter: Bonaca MP. The higher rate of premature discontinuation of ticagrelor vs placebo in the PEGASUS-TIMI 54 of stable outpatients with prior MI is attributed to more frequent dyspnea and bleeding, according to a new study. Among patients who tolerated therapy for<a href="https://solaci.org/en/2015/11/20/pegasus-timi-54-subanalysis-discontinuation-of-ticagrelor-mostly-due-to-dyspnea-or-bleeding/" title="Read more" >...</a>

IVUS-XPL: IVUS superior to angiography for guiding DES implantation in long lesions

Original Title: Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. Presenter: Hong S-J. Patients with long coronary lesions have better clinical results after a year of second generation DES implantation when interventions are guided by IVUS, instead of angiography. The benefit was attributed to a lower revascularization rate of ischemia<a href="https://solaci.org/en/2015/11/20/ivus-xpl-ivus-superior-to-angiography-for-guiding-des-implantation-in-long-lesions/" title="Read more" >...</a>

OPTIDUAL: Dual Antiaggregation Not Beneficial after 12 Months.

Extending dual antiaggregation therapy (DAT) from 12 to 48 months appears not to offer extra protection after DES implantation in patients with no adverse ischemic events during the first year, neither does it increase the risk of severe bleeding. The OPTIDUAL study was carried out in 58 centers and included 1.385 patients one year after<a href="https://solaci.org/en/2015/11/16/optidual-dual-antiaggregation-not-beneficial-after-12-months/" title="Read more" >...</a>

Meta-analysis of prolonged DAT after DES

Extending the antiaggregation therapy over a year reduces adverse events in patients with a history of AMI, according to this meta-analysis simultaneously published in the European Heart Journal. They analyzed data from 33.435 patients (mean age 64; 24% women) with a history of infarction included in one of the following clinical trials: CHARISMA, PRODIGY, ARCTIC-Interruption,<a href="https://solaci.org/en/2015/11/16/meta-analysis-of-prolonged-dat-after-des/" title="Read more" >...</a>

PEGASUS-TIMI 54: Ticagrelor plus ASA in stable patients

This double-blind study included 21162 patients with a history of acute myocardial infarction randomized to ticagrelor 90 mg e/12 h, ticagrelor 60 mg e/12 h or placebo. All patients received aspirin and had additional risk factors such as age or diabetes. The history of infarction should be between one and three years before being included<a href="https://solaci.org/en/2015/06/24/pegasus-timi-54-ticagrelor-plus-asa-in-stable-patients/" title="Read more" >...</a>

Reduction of ischemic events after 30 months of prasugrel following TAXUS stent implantation

Article The TAXUS Libert&eacute; Post Approval study included patients treated with TAXUS paclitaxel DES receiving prasugrel for 12 to 30 months. Primary end point was a combination of death, infarction or stroke that resulted in 3.7% after 30 months vs. 8.8% after 12 months of prasugrel administration (p&lt;0.001). Death and stroke rates were similar between<a href="https://solaci.org/en/2015/06/24/reduction-of-ischemic-events-after-30-months-of-prasugrel-following-taxus-stent-implantation/" title="Read more" >...</a>

Top